Anti-Diabetes Drugs - Netherlands

Netherlands

The projected revenue in the Anti-Diabetes Drugs market for the Netherlands is expected to reach €0.47bn in 2024.
It is anticipated that the revenue will exhibit an annual growth rate (CAGR 2024-2029) of 7.67%, leading to a market volume of €0.68bn by 2029.
In terms of global comparison, United States is predicted to generate the highest revenue in the market, amounting to €35,090.00m in 2024.
The Netherlands is experiencing a surge in demand for innovative anti-diabetes drugs, driven by a proactive healthcare system and a high prevalence of diabetes in the country.

Key regions: India, Australia, Italy, Europe, Brazil

Mercado

Región

Comparación de regiones

Moneda

Analyst Opinion

The demand for Anti-Diabetes Drugs in the Netherlands has been increasing steadily in recent years.

Customer preferences: The Netherlands has a high prevalence of diabetes, with over 1 million people suffering from the disease. As a result, there is a high demand for Anti-Diabetes Drugs in the country. Patients in the Netherlands prefer drugs that are effective, have minimal side effects, and are affordable.

Trends in the market: In recent years, there has been a shift towards using newer and more advanced drugs in the treatment of diabetes. These drugs offer better efficacy and fewer side effects compared to traditional drugs. The use of combination therapies has also been on the rise, with doctors prescribing multiple drugs to achieve better glycemic control.

Local special circumstances: The Dutch healthcare system is highly regulated, with the government playing a significant role in the pricing and reimbursement of drugs. This has led to a focus on cost-effectiveness in the selection of drugs, with cheaper alternatives often preferred over more expensive ones.

Underlying macroeconomic factors: The Netherlands has a strong economy, with a high standard of living and a well-developed healthcare system. The aging population and the high prevalence of diabetes have contributed to the growth of the Anti-Diabetes Drugs market in the country. Additionally, the Dutch government has been investing heavily in healthcare, which has led to an increase in the availability of drugs and better access to healthcare services for patients.

Methodology

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.